Home / Health / FDA Warns Savannah Chrisley Over Weight Loss Claims
FDA Warns Savannah Chrisley Over Weight Loss Claims
4 Mar
Summary
- FDA issued a warning letter to Savannah Chrisley last month.
- Claims about compounded semaglutide and tirzepatide were scrutinized.
- Chrisley's site has since updated wording to comply with FDA guidance.
Savannah Chrisley's prescription weight loss website, GoodGirlRX, is currently under federal review. Last month, the Food and Drug Administration (FDA) dispatched a warning letter to Chrisley regarding her site's marketing practices.
The FDA specifically flagged claims about compounded semaglutide and tirzepatide products. Phrases such as "FDA-approved meds" and "clinically proven GLP-1 results" were deemed misleading by the agency.
In its letter, the FDA explained that compounded drug products are not FDA-approved and that the website implied unverified safety and effectiveness. Chrisley was informed of her violation of federal law and given 15 business days to rectify the issues or face potential legal consequences.
Savannah Chrisley appears to have heeded the warning. Her website now reportedly uses phrases like "clinically studied results" and includes disclaimers stating the GLP-1 drugs are not FDA-approved. Chrisley told a media outlet that the issue was with website wording, not patient safety, and that the company welcomes the FDA's guidance.
